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Abstract
Influenza is a contagious respiratory illness that causes significant human mor-
bidity and mortality, affecting 5-15% of the population in a typical epidemic
season. Human influenza epidemics are caused by types A and B, with roughly
25% of human cases due to influenza B. Influenza B is a single-stranded RNA
virus with a high mutation rate, and both prior immune history and vaccina-
tion put significant pressure on the virus to evolve. Due to the high rate of viral
evolution, the influenza B vaccine component of the annual influenza vaccine is
updated, roughly every other year in recent years. To predict when an update
to the vaccine is needed, an estimate of expected vaccine effectiveness against
a range of viral strains is required. We here introduce a method to measure
antigenic distance between the influenza B vaccine and circulating viral strains.
The measure correlates well with effectiveness of the influenza B component of
the annual vaccine in humans between 1979 and 2014. We discuss how this
measure of antigenic distance may be used in the context of annual influenza
vaccine design and prediction of vaccine effectiveness.
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1. Introduction
Influenza is a highly contagious respiratory illness that infects all ages. It
occurs seasonally worldwide, causing substantial morbidity and mortality [1]. In
humans, influenza A/H3N1, A/H1N1, and B are the main causative agents. In
each influenza season, influenza A generally spreads widely. Influenza B tends
to be regionally dominant, causing seasonal epidemics every 2–4 years [2, 3].
The major molecular factors of influenza accessible to the immune system are
hemagglutinin and neuraminidase. Entry into host cells requires hemagglutinin,
which is also the main target of neutralizing antibodies [4, 5]. To protect against
influenza infections, the World Health Organization (WHO) recommends the
trivalent seasonal influenza vaccine, which includes the two main influenza type
A strains, H1N1 and H3N2, and an influenza B strain from the Yamagata or Vic-
toria lineages [6]. Hemagglutinin undergoes antigenic drift because of selective
pressure, and this drift reduces vaccine effectiveness.
Influenza B virus is less prevalent than influenza A, and the morbidity and
mortality associated with influenza B are often perceived to be lower than those
caused by influenza A. Nonetheless, influenza B has attracted researchers’ atten-
tion in recent years. An early modeling study with a two-tiered phylodynamic
model for influenza B compared the evolution of A/H3N2, A/H3N8, and B [7].
In some recent studies, influenza A and B infections resulted in similar mor-
bidity and mortality in hospitalized adults [8], and also caused similar clinical
characteristics in outpatients [9]. These results indicate that influenza B virus
can cause infections as severe as those caused by influenza A.
Influenza B is comprised of two distinct evolutionary lineages: B/Yamagata/16/88-
like and B/Victoria/2/87-like. These two lineages have co-circulated since the
1980s [10, 11]. The lineage that predominates can change yearly. In the USA,
there were 5 changes of the predominant lineage in the 10 seasons between 2001
and 2010 [12], often resulting in a mismatch between the vaccine strain and the
dominant circulating strain. There is limited to no protection of a vaccine for
one lineage against a viral strain from the other lineage. Moreover, the pro-
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tection of a vaccine for one lineage against viruses within that same lineage is
not uniform, as it depends on the antigenic distance between the vaccine and
virus. Compared to influenza A, there are relatively few studies of the relation
between antigenic distance and vaccine effectiveness for influenza B.
We here introduce a method to estimate antigenic distance between the in-
fluenza B vaccine and circulating viral strains. Epitope regions were mapped
from a standard influenza A/H3N2 virus. Additional amino acid sites that
exhibited high entropy in influenza B sequences sampled from the human pop-
ulation were added to the epitope regions. Note that while the binding of a
specific antibody in a specific individual against a specific antigen is typically
dominated by 5–6 contacting amino acid residues in the antigen, here we con-
sider typical regions of antibody binding among a distribution of 108 antibodies
and a distribution of 7 × 109 people and against a mixture of antigens within
a given influenza B strain. This is the reason for the rather large size of the
generalized epitopes A-E in the hemagglutinin protein considered here. We here
define an estimate of antigenic distance between the vaccine strain and the dom-
inant circulating strain as pepitope, the fraction of amino acid site substitutions
between the vaccine and circulating virus lineage in the dominant epitope region
of HA1 [13]. We will show that this measure of antigenic distance correlates well
with effectiveness of the influenza B component of the annual vaccine between
1979 and 2014.
To additionally detect the emergence of new influenza strains in the human
population, we built a dimensionally reduced space using the multidimensional
scaling method. This reduced space allowed for the visualization of the evolu-
tion of influenza B. In this representation, the emergence of new vaccine strain
clusters is apparent. In particular, clades appear in this representation at anti-
genic distances sufficiently far from current dominating strains that immune
recognition is ineffective.
This study provides a method to estimate influenza B antigenic distance and
vaccine effectiveness. The measure of antigenic distance introduced here, which
provides a novel tool for prediction of vaccine effectiveness in influenza B, may
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be used in the context of annual influenza vaccine design.
2. Methods
2.1. Sequence Data
Influenza B hemagglutinin protein sequences from human hosts in all regions
were downloaded from the Influenza Virus Database of the National Center for
Biotechnology Information (NCBI) [14]. Data were collected for the years 1979
to 2014. Only data containing the entire HA1 sequence were used.
2.2. Vaccine Strain and Circulating Strain
For each season, and for each epidemiological study, we determined the rel-
evant vaccine strain and the relevant dominant circulating strain. For those
studies that specified the vaccine strain used and the dominant circulating strain
observed, we used those sequences. For the studies conducted in the USA that
did not specify the strains, we used the vaccine strain and dominant circulat-
ing strain identified in the Center for Diseases Control and Prevention (CDC)
”Morbidity and Mortality Weekly Report”. For the remaining studies, we used
the vaccine strain and dominant circulating strain identified in the annual WHO
reports on ”recommendations on the composition of influenza virus vaccines.”
We note that the vaccine and dominant circulating strains changed from year
to year and from Northern to Southern Hemisphere studies.
2.3. Sequence Alignment
In each season, and in each epidemiological study, we determined whether
the vaccine strain was a Yamagata or Victoria lineage strain. To do this, we
first determined the lineage to which the vaccine strain belonged from the WHO
report [6]. If the report was inconclusive, we used the lineage assigned by the
Influenza Virus Database. If the database was inconclusive as well, typically
only for the sequences from early years, we used the phylogenetic tree calcu-
lated by the maximum likelihood method of MEGA 6.06 [15] to determine the
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lineage to which a strain belonged. For each lineage, we used a standard crys-
tal structure of HA1 to align the strains. For the Yamagata-like lineage, we
used B/Yamanashi/166/1998 (PBD ID: 4M44). For the Victoria-like lineage,
we used B/Brisbane/60/2008 (PBD ID: 4FQM). All protein sequences from a
given Northern or Southern Hemisphere influenza season were aligned to the
sequence determined by this procedure. The sequences were numbered with
reference to these standards, with the first amino acid site of each model amino
acid site 1. The Victoria sequence is one amino acid longer than the Yamagata
model, and multi-sequence alignment using PRANK [16] showed a gap at amino
acid site 163 in the Yamagata model.
The crystal structures of the two models are similar, with average root mean
square deviation between them of 0.3671 A˚.There are six missing amino acid
sites in the crystal structure of 4FQM and three missing amino acid sites in
the structure of 4M44. These amino acid sites are in the tail region. They
are far away from the epitope region and are not included in root mean square
deviation calculations.
2.4. Epitope Mapping
We here mapped the epitopes of both Yamagata-like and Victoria-like in-
fluenza B virus from the 5 epitopes of the H3 subtype of influenza A virus
[17, 18, 19, 20, 13, 21, 22] using PRANK, which allows for gaps in the alignment
and takes evolutionary distances into account [16]. We note that various modifi-
cations of these epitopes have been proposed, which range from relatively minor
additions of amino acid sites [23], to dramatic reassignments [24]. The latter is
discussed in our previous study [25], and we note here that measures of antigenic
distance based upon it correlate less well with A/H3N2 vaccine effectiveness in
humans than do those based upon the original epitope definition.
We used the sequence and numbering of A/California/7/2004 for the refer-
ence, as in the H1N1 mapping studies [21, 22]. If an epitope amino acid site
in A/California/7/2004 aligned to a gap in the influenza B model, that epitope
amino acid site was deleted in the influenza B model. If an epitope amino acid
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site in A/California/7/2004 aligned to multiple amino acid sites in the influenza
B model, because of a gap in A/California/7/2004 adjacent to the epitope amino
acid site, then further analysis was undertaken. The amino acid site before the
gap and all the amino acid sites in the gap in the influenza B model were consid-
ered as potential epitope amino acid sites. The amino acid sites with the highest
seasonal entropy, as described more fully in the Supplemental Information, were
selected as the final epitope amino acid sites. Numbers of sequences per year
are shown in Table S1.
2.5. Antigenic Distance between the Vaccine Strain and the Dominant Circu-
lating Strain
The antigenic distance between the vaccine strain and the dominant circulat-
ing strain was measured by pepitope, the fraction of amino acids in the dominant
epitope region of HA1 that differ between the vaccine and circulating strain [13].
We additionally considered several alternative definitions of antigenic distance.
The first is pall epitopes, the fraction of amino acid substitutions in the entire set
of all five epitope regions. The second is psequence, the fraction of amino acid
substitutions in the entire HA1 sequence. The third is ptwo epitopes, introduced
in this study, which is the fraction of amino acid substitutions in the two epi-
topes with the highest individual amino acid substitution fractions. The model,
Yamagata or Victoria, used in these calculations was that of the lineage to which
the vaccine strain belongs for the influenza season under consideration. If there
was a lineage mismatch when the vaccine strain was Victoria, the gap to which
amino acid site 163 mapped was considered as a amino acid site substitution.
If there was a lineage mismatch when the vaccine strain was Yamagata, amino
acid site 163 of the dominant strain, which mapped to a gap on the vaccine,
was excluded from the substitution computation.
2.6. Estimation of Vaccine Effectiveness
Vaccine effectiveness data were collected from the epidemiological literature.
Data were collected from mostly healthy adults, typically aged 18–65. Epidemi-
ological studies of influenza B are less common than those of influenza A, so
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studies with ideal experimental design are fewer in number. In roughly half
of the studies used here, there was a minority of subjects in the range of 13%
to 30% with conditions such as pregnancy, cardiovascular disease, diabetes, or
body mass index of 40 kg/m2 or greater. Interestingly, in all studies, the fraction
of subjects testing positive for influenza B was higher in the subjects without
comorbidity than in the subjects with comorbidity. All data on infections are
from laboratory-confirmed samples, e.g. by RT-PCR or the HI test. Studies fo-
cusing on elderly people and children were excluded to avoid noise caused by the
response of an immature immune system in children or the immunosenescence
phenomenon in elder people. Only studies that used an inactivated vaccine,
such as trivalent inactivated vaccine (TIV), were considered, to decrease bias
caused by differences of vaccine type. The epidemiological data were grouped
by season. For each study, the vaccine effectiveness was calculated from [13]
E =
u− v
u
(1)
where u is the rate at which unvaccinated people are infected with influenza,
and v is the rate at which vaccinated people are infected with influenza, with
u = nu/Nu and v = nv/Nv, where the total number of vaccinated subjects
is Nv, the total number of unvaccinated subjects is Nu, the number of in-
fluenza B cases among the vaccinated subjects is nv, and the number of in-
fluenza B cases among the unvaccinated subjects is nu. Binomial statistics
were assumed to calculate the error bars for the estimated effectiveness [13]:
ε =
√
σ2v/u
2/Nv + (v/u2)2σ2u/Nu, where σ
2
v = v(1− v) and σ2u = u(1− u). For
seasons that contained N studies, we used the average of the N effectiveness
values, and the standard error was ε =
√∑
i ε
2
i /N
2 where εi is the standard
error of the ith study.
2.7. Sequence Clustering Analysis
To gain a geometric understanding of historical influenza B evolution, we
clustered the Influenza Virus Database HA1 sequences from the years 1960 to
2014. The multidimensional scaling method was used to reduce the sequences
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from 348 amino acid dimensions to the 3 or 4 dimensions that best reproduce
the Hamming distances between all sequences [26]. Details of this dimensional
reduction are provided in the Supplemental Information.
3. Results
3.1. Epitope Determination
The composition of the five epitope regions in the Victoria and Yamagata
models were determined (Table 1). Note that amino acid site 163 in the Victo-
ria model (B/Brisbane/60/2008) corresponds to a gap in the Yamagata model
(B/Yamanashi/166/1998). Thus, amino acid site number i, i ≥ 164, in the
Victoria model corresponds to amino acid site number i − 1 in the Yamagata
model. In this table, the six amino acid sites that were added to the epitope
by the entropy criterion are shown in red. Additionally, the eight amino acid
sites that were added to the epitope by both the entropy criterion and RSA are
shown in red as well as in bold style. In epitopes A, B, and D there are two
added high-entropy surface amino acid sites each. In epitope C and E, there is
one amino acid site added to each epitope region.
In the Victoria model, there are 22 amino acids in epitope A, 25 in epitope
B, 23 in epitope C, 40 in epitope D and 25 in epitope E. In the Yamagata model,
epitope sizes of A, C, D, and E are the same as in the Victoria model, while
epitope B is 24 amino acids due to the gap.
3.2. Lineage Model Chosen
The main difference between the Victoria and Yamagata lineages is the gap of
amino acid site 163 (Victoria numbering). This gap cannot be ignored because
it is on epitope B, while the nearby amino acid sites 160 to 165 are also on
epitope B. We used the methods described in Section 2.5 to estimate the vaccine
effectiveness from several sequence-based measures of antigenic distance. When
the vaccine lineage is Yamagata, amino acid site 163 (Victoria numbering) is
eliminated from the antigenic distance calculation.
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3.3. Vaccine Effectiveness Correlates with Antigenic Distance
The influenza B vaccine effectiveness values calculated by Eq. 1 from epi-
demiological studies are listed in Table 2. This table also presents the antigenic
distances calculated from the epitopes defined above between the vaccine strain
and the dominant circulating strain. Three additional measures of distance
are also listed: ptwo epitopes, pall epitopes, and psequence. Figure 1 represents how
vaccine effectiveness declines with antigenic distance. A linear least squares fit
shows that E = −0.864 pepitope + 0.6824.
From this equation, the antigenic distance at which vaccine effectiveness de-
clines to zero is pepitope = 0.79. Using the size of each epitope and the frequency
with which each epitope is dominant from Table 2, we calculated the average
number of amino acid substitutions to which this value of pepitope corresponds
(see Table S3), 19 for the pepitope metric. The number of substitutions at which
the expected vaccine effectiveness declines to zero according to the linear least
squares fits for the other three measures of antigenic distance are also displayed
in this table.
A further sensitivity analysis was performed, limiting the data to laboratory
genetically confirmed samples, such as by RT-PCR. There were 19 out of 25
data points meeting this requirement. The linear least squares fit using only
those data is E = −0.8252 pepitope + 0.684, and R2 = 0.58. This result is quite
similar to that of Figure 1a, thus demonstrating limited sensitivity to such a
data restriction. Since RT-PCR was lacking mostly in the early years, 1979-
1988, and a relatively small fraction of the population was vaccinated in those
years, the bias stemming from HI is expected to be relatively small.
3.4. Dynamics of Influenza B Evolution
Multidimensional scaling was used to reduce the dimensions to the three
most informative dimensions. Figure 2a shows the evolution of influenza B
from 1960 to 2013. Numbers of sequences per year are shown in Table S2.
The left cluster and older points belong to the Victoria lineage, and the two
clusters on the right are from the Yamagata lineage. This Figure illustrates
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that the influenza B strain split into the two Victoria and Yamagata lineages in
the 1980s, both of which started to co-circulate from that time. Figure 2a also
suggests that the initial Yamagata lineage from the 1980s gave way to a distinct
daughter lineage around 2000. Note that the third dimension is necessary to
resolve this splitting of the Yamagata lineage. Analysis of the phylogenetic tree
is consistent with the clustering result shown in Figs. 2 and 3.
Because of the small difference in the eigenvalue associated with the third
dimension and the fourth dimension, we also reduced the dimensions to a 4D
space. Figure 2b shows the evolution, while the color coding represents the
fourth dimension. This Figure shows that the Yamagata strain jumped out and
back in the fourth dimension in the late 90s.
Two contour graphs were obtained from the Gaussian kernel density estima-
tion. The results are shown in Figure 3. Figure 3a is the x-y axis projection, and
Figure 3b is the x-z projection. Several representative influenza B sequences are
indicated. From Figure 3, we can measure the distance between peaks, the evi-
dent clusters in density estimation. We measured the average distance between
the major cluster transitions, shown as the dark lines in Figure 3. The average
number of substitutions is approximately 12. We also measured the full width
at half maximum for the major clusters. We find a width of approximately
6 substitutions. The corresponding peak-peak distance and cluster width for
H3N2 are 6 and 3 amino acids, respectively. [27]
3.5. Distribution of Epitopes and High-Entropy Residues
Figure 4a reveals the HA1 domain of influenza B (PDB ID:4FQM). This
structure is for the Victoria-like lineage. The structure for the Yamagata-like
lineage is visually indistinguishable. The five epitopes are represented as five
space-filling regions with distinct colors. The epitope amino acid sites are on the
surface of HA1. Figure 4b shows the 8 amino acid sites added to the epitope
region because of both high seasonal-average entropy and large RSA. These
additional amino acid sites are color coded according to the five epitopes, as in
Figure 4a. Figure S2 shows the average seasonal entropy of each amino acid in
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sequence of the HA1 domain. Each amino acid site is color coded according to
the five epitopes.
3.6. Dispersed Dominant Epitope in Each Season
The dominant epitope varies by season. Table S4 describes the fractional
change of each epitope in each season, sorted according to magnitude. By
definition, the first column is pepitope. Epitope B was most frequently dominant
(7 seasons), although A was also quite frequently dominant (6 seasons). Epitope
C always had the least fractional change. The next most dominant epitope also
varies by seasons: it could be A, B, D, or E. Note that the dominant and next
most dominant epitopes could have similar fractional changes in amino acids,
such as in 2012-2013 (b) and 2011-2012 (b).
3.7. Evolution of Influenza B
In this study, we used dimensional reduction to characterize the evolution
of influenza B. Phylogenetic trees are consistent with these results. We con-
structed a neighbor joining tree and a maximum likelihood tree based on the
same sequence set for which we performed dimensional reduction. In these trees
the Yamagata lineages and Victoria lineages are divided into two branches in
the tree, originating from sequences obtained in the 1980s. These trees are very
dense, however, and are hard to use to distinguish distances between clusters.
Thus, we provide a simplified phylogenetic tree in Figure S1. We can see the
Yamagata and Victoria branches in Figure S1. The distances among each clus-
ter and sub-cluster in the dimensionally reduced space are clearer than what the
trees can provide. The dimensionally reduced space is an optimal representation
of relative distances, unlike the phylogenetic trees that are constrained to a tree
topology.
We further analyzed the distance among peaks in our Gaussian kernel density
estimation. Based on Figure 3, the average distance between major peaks in
the same lineage is approximately 12 amino acid sites. In this analysis, peaks
in Victoria lineage and peaks in Yamagata lineage were measured separately.
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Influenza B strains in the early years belonged to the Victoria lineage and then
separated to two lineages in the 1980s. There is a small transitional peak in
between these two lineage clusters The distance between these two lineages is
approximately twice the average distance of 12 amino acid sites.
4. Discussion
4.1. Antigenic Distance at which Vaccine Effectiveness is Zero
The number of substitutions at which vaccine effectiveness is predicted to
decline to zero is shown in Table S3. For the pepitope estimate, vaccine effec-
tiveness decays to zero at roughly 19 substitutions. This result of the pepitope
estimate is the closest to the average distance observed between the evolving
strain clusters in the dimensional reduction analysis, 12 amino acid sites. Thus,
we chose pepitope as our metric for antigenic distance. In a previous study of
H3 in influenza A [27], the average distance between consecutive H3 clusters
was 6 amino acid sites, and the average substitution number when vaccine ef-
fectiveness decreases to zero was approximately 4. It appears influenza clusters
emerge at just enough distance to evade prior immunity, whether induced by
prior infection or vaccination in the human population.
4.2. Lower Selective Pressure Compared to Influenza A
Influenza A has high selection pressure, high mutant rate, and distinct dom-
inant epitopes in each season [21, 22, 25]. Influenza A is generally more common
than influenza B. Influenza B can, however, predominate in certain regions in
each influenza season [6, 28]. Since influenza A is widely predominant, it may
be under more selective pressure to evolve. The influenza A vaccine commonly
contains one lineage from A/H1N1 and one from A/H3N2 [6]. These vaccines
cause antibodies bind to the virus in a specific manner and stimulate the evolu-
tion of the dominant epitope. Vaccine and prior immune history are likely the
reasons for the distinct dominant epitopes in influenza A.
Unlike influenza A, the dominant epitopes of influenza B are not clear, and
the high-entropy amino acid sites are dispersed. These results indicate that
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selective pressure of influenza B may be more dispersed on the protein surface.
For certain regions of the influenza B epitopes, the selective pressure may rela-
tively be low, and antibody binding may be in a more random pattern. These
results explain why in some seasons, the second most dominant epitope often
has a similar fraction of amino acid substitutions as the dominant epitope.
5. Conclusion
In this paper we have considered how influenza B vaccine effectiveness de-
pends on antigenic distance. We have defined a measure of antigenic distance
for influenza B, pepitope. This measure is defined as the fraction of amino acid
site substitutions between the vaccine and circulating virus lineage in the dom-
inant epitope region of HA1 [13]. This measure correlates well with influenza B
vaccine effectiveness in humans. We find that new, emergent strains of influenza
B tend to occur at large values of pepitope, for which immune recognition will
be minimal. In other words, influenza B evolves to escape immune recognition
due to prior infection or vaccination in the human population.
This measure of antigenic distance provides a novel tool for prediction of
vaccine effectiveness and may be used in the context of annual influenza vaccine
design. The dimensional reduction technique illustrated here can be used to
identify incipient dominant strains. In conjunction with other available data,
such as ferret animal data, the pepitope measure can be used to estimate whether
a new vaccine strain will be required, by measuring the antigenic distance be-
tween the existing vaccine strain and the incipient strain. The pepitope measure
applies to both the Victoria and Yamagata lineages. The pepitope measure of
antigenic distance may be used, again in conjunction with other available data,
to select which vaccine strain in each lineage would be predicted to be most pro-
tective against the distribution of predicted or observed circulating viral strains.
It is also possible to perform this prediction on a geographically localized scale,
predicting vaccines optimal for different parts of the world. The pepitope measure
of antigenic distance may also be used to select among egg-viable, “like” strains
13
for those predicted to be most antigenically similar to the desired vaccine strain.
These capabilities complement existing analysis of sequence and animal model
datasets.
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Table 1: Residues in epitope region of influenza B
Epitope Residue
A 121 122 123 125 126 134 135 136 137 139 141 142 144
146 147 148 149 150 151 155 157 177
B 127 129 133 160 161 162 163 164 165 166 168 172 174
196 197 198 199 200 202 203 204 206 207 208 209
Victoria model C 34 35 36 37 38 39 40 289 291 292 293 294 309 315
317 318 320 321 323 324 325 326 327
D 93 101 102 116 120 176 179 180 182 183 184 185 186
187 188 190 212 214 218 219 220 223 224 225 226
227 228 229 230 233 242 243 244 245 246 254 255
256 257 258
E 42 44 48 56 58 59 63 71 73 75 77 78 79 80 83 84 85
88 89 91 108 273 276 277 280
A 121 122 123 125 126 134 135 136 137 139 141 142 144
146 147 148 149 150 151 155 157 176
B 127 129 133 160 161 162 163 164 165 167 171 173 195
196 197 198 199 201 202 203 205 206 207 208
Yamagata model C 34 35 36 37 38 39 40 288 290 291 292 293 308 314
316 317 319 320 322 323 324 325 326
D 93 101 102 116 120 175 178 179 181 182 183 184 185
186 187 189 211 213 217 218 219 222 223 224
225 226 227 228 229 232 241 242 243 244 245 253 254
255 256 257
E 42 44 48 56 58 59 63 71 73 75 77 78 79 80 83 84 85
88 89 91 108 272 275 276 279
Residues in epitopes A, B, C, D, and E of influenza B. The results for both
the Victoria model (B/Brisbane/60/2008 numbering) and the Yamagata model
(B/Yamanashi/166/1998 numbering) are shown. The six amino acid sites that
were added to the epitope by the entropy criterion are shown in red. The eight
amino acid sites that were added to the epitope by both the entropy criterion
and relative accessible surface area (RSA) are shown in red bold.
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Figure 4: Epitopes and additional high-entropy amino acid sites on the HA1 3D structure
A B
a: Three dimensional structure of influenza B, HA1 domain (Victoria lineage,
model 4FQM) with five epitopes. Epitopes are shown in space filling represen-
tation with different colors corresponding to the five epitopes: epitope A (red),
epitope B (yellow), epitope C (orange), epitope D (blue), epitope E (green),
and non-epitope region (silver). b: Three dimensional structure of influenza B,
HA1 domain (Victoria lineage) with the 8 high-entropy amino acid sites newly
added to the epitope region: amino acid site 122 and 126 to epitope A, 166 and
209 to epitope B, 40 to epitope C, 233 and 255 to epitope D, and 73 to epitope
E. Here the Victoria numbering is used.
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1. Methods
1.1. Epitope Mapping
For influenza A/H3N2, it has been determined that there are 5 epitopes on
the HA1 protein that contribute significantly to the human immune response to
the virus [? ]. These epitopes have been identified by crystallography [? ? ] and
further improved by sequence analysis [? ? ]. Epitopes for the H1N1 strain of
influenza A have been determined by mapping from these H3N2 epitopes [? ? ].
The average root mean square deviation of the mapped epitope region between
influenza A/H3N2 and influenza B Victoria lineage is 3.1517 A˚, and the value
between influenza A/H3N2 and influenza B Yamagata lineage is 3.0931 A˚.
Amino acid sites in epitopes are under selective pressure, which stimulates
their evolution to avoid recognition. This process increases the entropy value of
the amino acid sites in epitope regions. The Shannon entropy of these amino
acid sites per season was calculated using worldwide HA1 sequences collected
during every Northern Hemisphere influenza season (September to March) from
1994-1995 season to 2013-2014 season, and then averaged over all seasons. For
each epitope amino acid site of influenza A mapping to multiple amino acid sites
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in influenza B, the amino acid site with the highest average seasonal Shannon
entropy was included in the epitope [? ]. Additionally, those amino acid sites
with an average seasonal Shannon entropy greater than 0.1 were included. This
threshold of information entropy is determined adaptively. Listing amino acid
sites in descending order of entropy, 0.1 is a boundary for non-random entropy
values.
We used this threshold to extend the epitope regions. A total of 15 amino
acid sites outside the mapped epitope region have an average seasonal Shannon
entropy greater than 0.1. We calculated the relative accessible surface area
(RSA) of them based on protein structure 4FQM using ASA view [? ]. We
included 8 amino acid sites with RSA greater than 0.5, which were considered
amino acid sites on the surface. These 8 amino acid sites were assigned to
epitopes by calculating the distance of alpha carbons between these amino acid
sites and the amino acid sites in epitope region respectively, assigning amino acid
sites to the closet epitope. For the Victoria model, amino acid site 126 belongs to
epitope A. However, amino acid site 126 was difficult to assign unambiguously in
the Yamagata model. The minimum distance with a amino acid site in epitope B
of the 4M44 Yamagata model was 3.794A˚, while the minimum distance between
amino acid site 126 and a amino acid site in epitope A is 3.808 A˚. Comparing
the ten closest epitopic amino acid sites to amino acid site 126 in 4M44, we
found that it is closer to epitope A on average. Therefore, we determined that
amino acid site 126 should be included in epitope A for the Yamagata model.
1.2. Sequence Clustering Analysis
The relative importance of each dimension in the multidimensional scaling is
proportional to the eigenvalue associated with each reduced dimension: 0.05562,
0.02411, 0.00692, and 0.00640.
In the calculation each sequence was weighted by the inverse of the number of
samples collected per year, to give each year roughly equal weight in the dimen-
sional reduction procedure. Additionally Gaussian kernel density estimation
was used to estimate the probability density of sequences in the reduced space
2
identified by the weighted multidimensional scaling. The standard deviation of
the Gaussian weight was σx=0.03351265, σy=0.01171378, and σz=0.01177186.
The reconstructed probability density of the viruses in the reduced (x, y, z)
space is P (x, y, z) ∝ ∑i exp[− (x−xi)22σ2x − (y−yi)22σ2y − (z−zi)22σ2z ]. The peaks in this
density estimate correspond to clusters of influenza B sequences. The fourth
dimension in the 4D figure is indicated by the color bar.
The phylogenetic tree of these sequences was constructed using MEGA 6.06
[? ]. A neighbor joining tree was first constructed. A maximum likelihood
tree was then constructed, whose structure confirmed that of the neighbor join-
ing tree. The maximum likelihood tree was divided into three groups: Two
Yamagata-like lineages and one Victoria-like lineage.
2. Discussion
2.1. Dispersed High Entropy Amino Acid Sites
The distribution of high-entropy amino acid sites is dispersed, spread on the
HA1 domain. Figure S2 represents the distribution of high entropy amino acid
sites in the sequence, and Figure 3 shows part of the high entropy amino acid
sites in the 3D structure. High entropy amino acid sites can be either inside
or outside the epitope region, and they appear in every epitope. Some of these
high entropy amino acid sites even have low RSA, indicating that they are not
fully exposed on the surface.
If we set a critical value of high-entropy as 0.1 [? ], we find that some of
these high-entropy amino acid sites do not cluster in any of the epitopes we
defined. The fraction of high-entropy amino acid sites in each epitope of the
Victoria model are 9 out of 22 in epitope A, 15 out of 25 in epitope B, 1 out of
23 in epitope C, 12 out of 40 in epitope D, and 8 out of 25 in epitope E, with
7 high-entropy amino acid sites outside the epitope region. These amino acid
sites are shown in Figure S2.
Re-clustering all the high-entropy amino acid sites did not improve the cor-
relation between vaccine effectiveness and antigenic distance. We analyzed se-
3
quence data from the original dataset of dimensional reduction and clustered
the behavior of high-entropy amino acid sites in each season into three novel
agglomerative clusters using Cluster Analysis of MATLAB [? ]. There was
no significant correlation among them and the original epitopes. Additionally,
vaccine effectiveness became zero at pepitope or pall epitopes values larger than 1.
We also calculated the antigenic distances when all the low-entropy amino
acid sites in epitopes were removed and correlated these antigenic distances
determined from high-entropy amino acid sites only with vaccine effectiveness.
Epitope C was removed as it contained only one high-entropy amino acid site.
Therefore, in the Victoria lineage, 44 high-entropy amino acid sites were taken
into account. The linear least squares fit of pepitope was E = −0.4408 pepitope +
0.6675, and pall epitopes was E = −0.5392 pall epitopes + 0.6735. The estimated
substitution number of pepitope was 13.03, similar to that in Figure 1, further
substantiating the pepitope is suitable as the measurement criteria. However,
for pall epitopes, vaccine effectiveness would not decline to zero even if all these
44 high-entropy amino acid sites are substituted. A linear least squares fit
of ptwo epitopes was E = −0.6662 ptwo epitopes + 0.6704. This result indicates
that when all of the amino acid sites in the two dominant epitope region are
mutated, vaccine effectiveness will decline to zero. Nonetheless, these high-
entropy amino acid sites contain only part of the surface amino acid sites. The
region potentially recognized by the immune system should cover the surface of
HA1. Thus, it is likely not enough to consider only high-entropy amino acid sites
only in epitope determination. We look forward to both more epidemiological
studies for influenza B and more sequence data to extend our dataset, in which
case an updated calculation of the high-entropy amino acid sites may more fully
cover the HA1 surface.
2.2. Role of High-Entropy Amino Acid Sites with low RSA
From Figure S2, our definition of the five epitopes includes most of the high
entropy amino acid sites. Though we have already considered the high-entropy
amino acid sites in epitope definition, we found that there are still some amino
4
acid sites with average seasonal entropy greater than 0.1, such as amino acid
site 262 and 267. The reason why they were not included is that they have a
low RSA, and they are not likely to be recognized by antibodies because they
are not on the surface of the protein.
We further tested if these amino acid sites can affect the correlation between
antigenic distance and vaccine effectiveness. Though they are not fully ex-
posed, substitutions in these amino acid sites could affect the epitope structure,
and substitutions of these amino acid sites could change the shape of antibody
recognition amino acid site, and affect vaccine effectiveness. We added these 7
high-entropy but low RSA amino acid sites to our 5 epitopes using the same
method as described in Section 1.1. In the Victoria numbering, amino acid site
262, 266, and 267 were added to epitope B, amino acid site 29 was added to
epitope C, amino acid sites 175 and 252 were added to epitope D, and amino
acid site 76 was added to epitope E. These modifications did not quantitatively
change the vaccine effectiveness and pepitope relation.
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Table 1: Number of sequences collected per year for the entropy analysis
Season Victoria Yamagata total
1994-1995 0 19 19
1995-1996 0 6 6
1996-1997 0 23 23
1997-1998 2 0 2
1998-1999 2 23 25
1999-2000 0 29 29
2000-2001 5 87 92
2001-2002 24 19 43
2002-2003 57 19 76
2003-2004 4 33 37
2004-2005 81 208 289
2005-2006 121 41 162
2006-2007 178 59 237
2007-2008 140 365 505
2008-2009 190 79 269
2009-2010 169 29 198
2010-2011 606 84 690
2011-2012 130 133 263
2012-2013 97 425 522
2013-2014 109 185 294
The number of sequences downloaded from GenBank in each September-March
season for the entropy analysis. The sequences are classified as either Victoria
or Yamagata strains.
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Table 2: Number of sequences collected per year for the dimensional reduction
Season total Season total
1960 1 1988 7
1961 2 1989 14
1962 2 1990 31
1963 2 1991 14
1964 3 1992 8
1965 2 1993 20
1966 2 1994 23
1967 2 1995 28
1968 2 1996 29
1969 2 1997 70
1970 2 1998 26
1971 2 1999 64
1972 2 2000 35
1973 3 2001 134
1974 4 2002 164
1975 1 2003 90
1976 4 2004 184
1977 2 2005 345
1978 2 2006 290
1979 2 2007 377
1980 2 2008 544
1981 3 2009 336
1982 6 2010 523
1983 4 2011 570
1984 3 2012 572
1985 8 2013 419
1986 7 2014 398
1987 9
The number of sequences downloaded from GenBank in each year for the di-
mensional reduction.
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Table 3: Predicted amino acid substitutions for which VE decreases to zero
Antigenic distances Average number of total amino acids Average number of substitution
at zero effectiveness at zero effectiveness
pepitope 0.79 24 19
ptwo epitopes 0.74 51 38
pall epitopes 0.43 135 57
psequence 0.20 347 69
The value of antigenic distance for which the predicted effectiveness decays to
zero is shown for different measures of antigenic distance. The number of sub-
stitutions at which the predicted effectiveness decays to zero from each measure
is also shown.
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Table 4: The dominant epitope varies by season
Seasons First three dominant epitopes pdominant epitope psecond dominant epitope pthird dominant epitope
2012–2013 (a) - - - -
2012–2013 (b) B E D 0.0833333 0.08 0.05
2012–2013 (c) A B E 0.363636 0.333333 0.24
2011–2012 (a) B A E 0.4 0.363636 0.24
2011–2012 (b) A B E 0.363636 0.36 0.24
2011–2012 (c) - - - -
2011 - - - -
2010 - - - -
2008–2009 A B E 0.363636 0.333333 0.28
2008 - - - -
2007–2008 B A E 0.4 0.363636 0.28
2006–2007 A B E 0.363636 0.36 0.24
2005–2006 (a) A B E 0.363636 0.333333 0.24
2005–2006 (b) A B E 0.454545 0.375 0.217
1987–1988 B D A 0.12 0.075 0.0454545
1985–1986 B D A 0.28 0.125 0.0909091
1983–1984 B D 0.12 0.025 0
1979–1980 B A E 0.12 0.0909091 0.04
The first three dominant epitopes in each year in descending order and the
antigenic distances associated with each epitope.
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Figure 1: Phylogenetic tree of representative influenza B strains
 B/Massachusetts/02/2012
 B/Florida/4/2006
 B/Shanghai/361/2002
 B/Sichuan/379/99
 B/Yamanashi/166/1998
 B/Harbin/7/1994
 B/Beijing/184/93
 B/Panama/45/90
 B/Hong Kong/22/1989
 B/Yamagata/16/1988
 B/Singapore/222/79
 B/Hong Kong/05/1972
 B/Ann Arbor/1/86
 B/Beijing/1/1987
 B/Victoria/2/87
 B/Hong Kong/330/2001
 B/Brisbane/60/2008
 B/Malaysia/2506/2004
Maximum likelihood phylogenetic tree of the 18 representative influenza B
strains highlighted in Figure 2.
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Figure 2: Seasonal average entropy distribution in HA1 sequence
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Seasonal average entropy distribution in HA1 sequence of influenza B. The Vic-
toria lineage (model 4FQM) numbering is used. Data were collected in every
Northern Hemisphere influenza season (September to March of the next year)
from 1994 to 2014, 20 seasons in total.
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